{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T03:24:50Z","timestamp":1794367490809,"version":"4.9.0"},"reference-count":268,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,8,13]],"date-time":"2020-08-13T00:00:00Z","timestamp":1597276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2020,8,13]],"date-time":"2020-08-13T00:00:00Z","timestamp":1597276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Dis Primers"],"DOI":"10.1038\/s41572-020-0196-7","type":"journal-article","created":{"date-parts":[[2020,8,13]],"date-time":"2020-08-13T04:05:54Z","timestamp":1597291554000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":573,"title":["Podocytopathies"],"prefix":"10.1038","volume":"6","author":[{"given":"Jeffrey B.","family":"Kopp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Joachim","family":"Anders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katalin","family":"Susztak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel A.","family":"Podest\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Remuzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedhelm","family":"Hildebrandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Romagnani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,13]]},"reference":[{"key":"196_CR1","first-page":"13","volume":"77","author":"N Pallet","year":"2019","unstructured":"Pallet, N. et al. Proteinuria typing: how, why and for whom? Ann. Biol. Clin. 77, 13\u201325 (2019).","journal-title":"Ann. Biol. Clin."},{"key":"196_CR2","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1093\/ndt\/gfu035","volume":"30","author":"S Sethi","year":"2015","unstructured":"Sethi, S., Glassock, R. J. & Fervenza, F. C. Focal segmental glomerulosclerosis: towards a better understanding for the practicing nephrologist. Nephrol. Dial. Transpl. 30, 375\u2013384 (2015).","journal-title":"Nephrol. Dial. Transpl."},{"key":"196_CR3","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1007\/s00108-019-0590-y","volume":"60","author":"J Muller-Deile","year":"2019","unstructured":"Muller-Deile, J., Schenk, H. & Schiffer, M. Minimal change disease and focal segmental glomerulosclerosis. Internist 60, 450\u2013457 (2019).","journal-title":"Internist"},{"key":"196_CR4","doi-asserted-by":"crossref","first-page":"502","DOI":"10.2215\/CJN.05960616","volume":"12","author":"AZ Rosenberg","year":"2017","unstructured":"Rosenberg, A. Z. & Kopp, J. B. Focal segmental glomerulosclerosis. Clin. J. Am. Soc. Nephrol. 12, 502\u2013517 (2017).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"196_CR5","doi-asserted-by":"crossref","first-page":"529","DOI":"10.2215\/CJN.04121206","volume":"2","author":"L Barisoni","year":"2007","unstructured":"Barisoni, L., Schnaper, H. W. & Kopp, J. B. A proposed taxonomy for the podocytopathies: a reassessment of the primary nephrotic diseases. Clin. J. Am. Soc. Nephrol. 2, 529\u2013542 (2007). This paper is the first proposal for the reclassification of podocytopathies.","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"196_CR6","doi-asserted-by":"crossref","first-page":"332","DOI":"10.2215\/CJN.05000516","volume":"12","author":"M Vivarelli","year":"2017","unstructured":"Vivarelli, M., Massella, L., Ruggiero, B. & Emma, F. Minimal change disease. Clin. J. Am. Soc. Nephrol. 12, 332\u2013345 (2017).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"196_CR7","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/sj.ki.5002222","volume":"71","author":"RC Wiggins","year":"2007","unstructured":"Wiggins, R. C. The spectrum of podocytopathies: a unifying view of glomerular diseases. Kidney Int. 71, 1205\u20131214 (2007).","journal-title":"Kidney Int."},{"key":"196_CR8","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1053\/j.ajkd.2016.03.416","volume":"68","author":"JJ Sim","year":"2016","unstructured":"Sim, J. J. et al. Distribution of biopsy-proven presumed primary glomerulonephropathies in 2000-2011 among a racially and ethnically diverse US population. Am. J. Kidney Dis. 68, 533\u2013544 (2016).","journal-title":"Am. J. Kidney Dis."},{"key":"196_CR9","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1093\/ndt\/gfp620","volume":"25","author":"F Pesce","year":"2010","unstructured":"Pesce, F. & Schena, F. P. Worldwide distribution of glomerular diseases: the role of renal biopsy registries. Nephrol. Dial. Transpl. 25, 334\u2013336 (2010).","journal-title":"Nephrol. Dial. Transpl."},{"key":"196_CR10","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1038\/s41591-018-0194-4","volume":"24","author":"C Qiu","year":"2018","unstructured":"Qiu, C. et al. Renal compartment-specific genetic variation analyses identify new pathways in chronic kidney disease. Nat. Med. 24, 1721\u20131731 (2018).","journal-title":"Nat. Med."},{"key":"196_CR11","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1681\/ASN.2014030247","volume":"26","author":"RA Gbadegesin","year":"2015","unstructured":"Gbadegesin, R. A. et al. HLA-DQA1 and PLCG2 are candidate risk loci for childhood-onset steroid-sensitive nephrotic syndrome. J. Am. Soc. Nephrol. 26, 1701\u20131710 (2015).","journal-title":"J. Am. Soc. Nephrol."},{"key":"196_CR12","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1681\/ASN.2017111185","volume":"29","author":"H Debiec","year":"2018","unstructured":"Debiec, H. et al. Transethnic, genome-wide analysis reveals immune-related risk alleles and phenotypic correlates in pediatric steroid-sensitive nephrotic syndrome. J. Am. Soc. Nephrol. 29, 2000\u20132013 (2018).","journal-title":"J. Am. Soc. Nephrol."},{"key":"196_CR13","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1681\/ASN.2018101054","volume":"30","author":"S Dufek","year":"2019","unstructured":"Dufek, S. et al. Genetic identification of two novel loci associated with steroid-sensitive nephrotic syndrome. J. Am. Soc. Nephrol. 30, 1375\u20131384 (2019).","journal-title":"J. Am. Soc. Nephrol."},{"key":"196_CR14","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1681\/ASN.2017080859","volume":"29","author":"X Jia","year":"2018","unstructured":"Jia, X. et al. Strong association of the HLA-DR\/DQ locus with childhood steroid-sensitive nephrotic syndrome in the Japanese population. J. Am. Soc. Nephrol. 29, 2189\u20132199 (2018).","journal-title":"J. Am. Soc. Nephrol."},{"key":"196_CR15","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1056\/NEJMoa1310345","volume":"369","author":"A Parsa","year":"2013","unstructured":"Parsa, A. et al. APOL1 risk variants, race, and progression of chronic kidney disease. N. Engl. J. Med. 369, 2183\u20132196 (2013).","journal-title":"N. Engl. J. Med."},{"key":"196_CR16","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1126\/science.1193032","volume":"329","author":"G Genovese","year":"2010","unstructured":"Genovese, G. et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 329, 841\u2013845 (2010).","journal-title":"Science"},{"key":"196_CR17","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s00439-010-0861-0","volume":"128","author":"S Tzur","year":"2010","unstructured":"Tzur, S. et al. Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene. Hum. Genet. 128, 345\u2013350 (2010).","journal-title":"Hum. Genet."},{"key":"196_CR18","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1590\/2175-8239-jbn-2017-0033","volume":"40","author":"TA Siemens","year":"2018","unstructured":"Siemens, T. A., Riella, M. C., Moraes, T. P. & Riella, C. V. APOL1 risk variants and kidney disease: what we know so far. J. Bras. Nefrol. 40, 388\u2013402 (2018).","journal-title":"J. Bras. Nefrol."},{"key":"196_CR19","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-015069","volume":"8","author":"S Abd ElHafeez","year":"2018","unstructured":"Abd ElHafeez, S. et al. Prevalence and burden of chronic kidney disease among the general population and high-risk groups in Africa: a systematic review. BMJ Open 8, e015069 (2018).","journal-title":"BMJ Open"},{"key":"196_CR20","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/MOT.0000000000000600","volume":"24","author":"FM Tedla","year":"2019","unstructured":"Tedla, F. M. & Yap, E. Apolipoprotein L1 and kidney transplantation. Curr. Opin. Organ. Transpl. 24, 97\u2013102 (2019).","journal-title":"Curr. Opin. Organ. Transpl."},{"key":"196_CR21","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.molmed.2018.05.008","volume":"24","author":"P Beckerman","year":"2018","unstructured":"Beckerman, P. & Susztak, K. APOL1: the balance imposed by infection, selection, and kidney disease. Trends Mol. Med. 24, 682\u2013695 (2018).","journal-title":"Trends Mol. Med."},{"key":"196_CR22","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/nm.4287","volume":"23","author":"P Beckerman","year":"2017","unstructured":"Beckerman, P. et al. Transgenic expression of human APOL1 risk variants in podocytes induces kidney disease in mice. Nat. Med. 23, 429\u2013438 (2017).","journal-title":"Nat. Med."},{"key":"196_CR23","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/ki.1997.29","volume":"51","author":"A Fogo","year":"1997","unstructured":"Fogo, A. et al. Accuracy of the diagnosis of hypertensive nephrosclerosis in African Americans: a report from the African American Study of Kidney Disease (AASK) Trial. AASK Pilot Study Investigators. Kidney Int. 51, 244\u2013252 (1997).","journal-title":"Kidney Int."},{"key":"196_CR24","doi-asserted-by":"crossref","first-page":"3162","DOI":"10.1681\/ASN.2014080752","volume":"26","author":"JB Hodgin","year":"2015","unstructured":"Hodgin, J. B. et al. Glomerular aging and focal global glomerulosclerosis: a podometric perspective. J. Am. Soc. Nephrol. 26, 3162\u20133178 (2015).","journal-title":"J. Am. Soc. Nephrol."},{"key":"196_CR25","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2174\/156652413804486250","volume":"13","author":"L Lasagni","year":"2013","unstructured":"Lasagni, L., Lazzeri, E., Shankland, S. J., Anders, H. J. & Romagnani, P. Podocyte mitosis - a catastrophe. Curr. Mol. Med. 13, 13\u201323 (2013).","journal-title":"Curr. Mol. Med."},{"key":"196_CR26","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/nrneph.2015.172","volume":"12","author":"BI Freedman","year":"2016","unstructured":"Freedman, B. I. & Cohen, A. H. Hypertension-attributed nephropathy: what\u2019s in a name? Nat. Rev. Nephrol. 12, 27\u201336 (2016). An extensive critical reassessment of the role of APOL1 not only in FSGS but also in hypertension-attributed nephropathy.","journal-title":"Nat. Rev. Nephrol."},{"key":"196_CR27","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1161\/CIRCULATIONAHA.118.036589","volume":"140","author":"AG Bick","year":"2019","unstructured":"Bick, A. G. et al. Association of APOL1 risk alleles with cardiovascular disease in blacks in the Million Veteran Program. Circulation 140, 1031\u20131040 (2019).","journal-title":"Circulation"},{"key":"196_CR28","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1093\/ndt\/gfr574","volume":"27","author":"JO Burton","year":"2012","unstructured":"Burton, J. O. et al. Association of anthropometric obesity measures with chronic kidney disease risk in a non-diabetic patient population. Nephrol. Dial. Transpl. 27, 1860\u20131866 (2012).","journal-title":"Nephrol. Dial. Transpl."},{"key":"196_CR29","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1093\/ndt\/16.9.1790","volume":"16","author":"M Praga","year":"2001","unstructured":"Praga, M. et al. Clinical features and long-term outcome of obesity-associated focal segmental glomerulosclerosis. Nephrol. Dial. Transpl. 16, 1790\u20131798 (2001).","journal-title":"Nephrol. Dial. Transpl."},{"key":"196_CR30","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1007\/s11684-017-0570-3","volume":"11","author":"T Xu","year":"2017","unstructured":"Xu, T., Sheng, Z. & Yao, L. Obesity-related glomerulopathy: pathogenesis, pathologic, clinical characteristics and treatment. Front. Med. 11, 340\u2013348 (2017).","journal-title":"Front. Med."},{"key":"196_CR31","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.kint.2017.02.032","volume":"91","author":"W Kriz","year":"2017","unstructured":"Kriz, W. & Lemley, K. V. Potential relevance of shear stress for slit diaphragm and podocyte function. Kidney Int. 91, 1283\u20131286 (2017).","journal-title":"Kidney Int."},{"key":"196_CR32","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nrneph.2016.75","volume":"12","author":"VD D'Agati","year":"2016","unstructured":"D\u2019Agati, V. D. et al. Obesity-related glomerulopathy: clinical and pathologic characteristics and pathogenesis. Nat. Rev. Nephrol. 12, 453\u2013471 (2016).","journal-title":"Nat. Rev. Nephrol."},{"key":"196_CR33","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1681\/ASN.2016060666","volume":"28","author":"L Tonneijck","year":"2017","unstructured":"Tonneijck, L. et al. Glomerular hyperfiltration in diabetes: mechanisms, clinical significance, and treatment. J. Am. Soc. Nephrol. 28, 1023\u20131039 (2017).","journal-title":"J. Am. Soc. Nephrol."},{"key":"196_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-020-0256-y","author":"V Vallon","year":"2020","unstructured":"Vallon, V. & Thomson, S. C. The tubular hypothesis of nephron filtration and diabetic kidney disease. Nat. Rev. Nephrol. https:\/\/doi.org\/10.1038\/s41581-020-0256-y (2020).","journal-title":"Nat. Rev. Nephrol."},{"key":"196_CR35","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1056\/NEJM199110103251502","volume":"325","author":"AC Novick","year":"1991","unstructured":"Novick, A. C., Gephardt, G., Guz, B., Steinmuller, D. & Tubbs, R. R. Long-term follow-up after partial removal of a solitary kidney. N. Engl. J. Med. 325, 1058\u20131062 (1991).","journal-title":"N. Engl. J. Med."},{"key":"196_CR36","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/BF00873996","volume":"6","author":"LR Argueso","year":"1992","unstructured":"Argueso, L. R. et al. Prognosis of patients with unilateral renal agenesis. Pediatr. Nephrol. 6, 412\u2013416 (1992).","journal-title":"Pediatr. Nephrol."},{"key":"196_CR37","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/S0140-6736(17)30576-7","volume":"390","author":"VA Luyckx","year":"2017","unstructured":"Luyckx, V. A. et al. A developmental approach to the prevention of hypertension and kidney disease: a report from the Low Birth Weight and Nephron Number Working Group. Lancet 390, 424\u2013428 (2017). A position paper that supports the essential role of nephron mass in determining the risk for FSGS and CKD.","journal-title":"Lancet"},{"key":"196_CR38","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1007\/s00467-011-1857-2","volume":"26","author":"B Aygun","year":"2011","unstructured":"Aygun, B., Mortier, N. A., Smeltzer, M. P., Hankins, J. S. & Ware, R. E. Glomerular hyperfiltration and albuminuria in children with sickle cell anemia. Pediatr. Nephrol. 26, 1285\u20131290 (2011).","journal-title":"Pediatr. Nephrol."},{"key":"196_CR39","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1056\/NEJM198801073180102","volume":"318","author":"YT Chen","year":"1988","unstructured":"Chen, Y. T., Coleman, R. A., Scheinman, J. I., Kolbeck, P. C. & Sidbury, J. B. Renal disease in type I glycogen storage disease. N. Engl. J. Med. 318, 7\u201311 (1988).","journal-title":"N. Engl. J. Med."},{"key":"196_CR40","doi-asserted-by":"crossref","DOI":"10.1186\/s40697-015-0063-8","volume":"2","author":"C Morgan","year":"2015","unstructured":"Morgan, C., Al-Aklabi, M. & Garcia Guerra, G. Chronic kidney disease in congenital heart disease patients: a narrative review of evidence. Can. J. Kidney Health Dis. 2, 27 (2015).","journal-title":"Can. J. Kidney Health Dis."},{"key":"196_CR41","first-page":"233","volume":"60","author":"JA Schwimmer","year":"2003","unstructured":"Schwimmer, J. A. et al. Secondary focal segmental glomerulosclerosis in non-obese patients with increased muscle mass. Clin. Nephrol. 60, 233\u2013241 (2003).","journal-title":"Clin. Nephrol."},{"key":"196_CR42","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1097\/01.ASN.0000039661.06947.FD","volume":"13","author":"P Mundel","year":"2002","unstructured":"Mundel, P. & Shankland, S. J. Podocyte biology and response to injury. J. Am. Soc. Nephrol. 13, 3005\u20133015 (2002).","journal-title":"J. Am. Soc. Nephrol."},{"key":"196_CR43","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1005433","volume":"13","author":"CV Falkenberg","year":"2017","unstructured":"Falkenberg, C. V. et al. Fragility of foot process morphology in kidney podocytes arises from chaotic spatial propagation of cytoskeletal instability. PLoS Comput. Biol. 13, e1005433 (2017).","journal-title":"PLoS Comput. Biol."},{"key":"196_CR44","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s11892-016-0735-5","volume":"16","author":"JS Lin","year":"2016","unstructured":"Lin, J. S. & Susztak, K. Podocytes: the weakest link in diabetic kidney disease? Curr. Diab Rep. 16, 45 (2016).","journal-title":"Curr. Diab Rep."},{"key":"196_CR45","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2337\/diabetes.55.01.06.db05-0894","volume":"55","author":"K Susztak","year":"2006","unstructured":"Susztak, K., Raff, A. C., Schiffer, M. & Bottinger, E. P. Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes 55, 225\u2013233 (2006).","journal-title":"Diabetes"},{"key":"196_CR46","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s00467-016-3358-9","volume":"32","author":"W Kriz","year":"2017","unstructured":"Kriz, W. & Lemley, K. V. Mechanical challenges to the glomerular filtration barrier: adaptations and pathway to sclerosis. Pediatr. Nephrol. 32, 405\u2013417 (2017).","journal-title":"Pediatr. Nephrol."},{"key":"196_CR47","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1007\/s00424-017-2025-8","volume":"469","author":"K Endlich","year":"2017","unstructured":"Endlich, K., Kliewe, F. & Endlich, N. Stressed podocytes-mechanical forces, sensors, signaling and response. Pflug. Arch. 469, 937\u2013949 (2017).","journal-title":"Pflug. Arch."},{"key":"196_CR48","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.2337\/db15-0260","volume":"64","author":"MT Sweetwyne","year":"2015","unstructured":"Sweetwyne, M. T. et al. Notch1 and Notch2 in podocytes play differential roles during diabetic nephropathy development. Diabetes 64, 4099\u20134111 (2015).","journal-title":"Diabetes"},{"key":"196_CR49","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1053\/j.ackd.2014.05.009","volume":"21","author":"JA Jefferson","year":"2014","unstructured":"Jefferson, J. A. & Shankland, S. J. The pathogenesis of focal segmental glomerulosclerosis. Adv. Chronic Kidney Dis. 21, 408\u2013416 (2014).","journal-title":"Adv. Chronic Kidney Dis."},{"key":"196_CR50","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1681\/ASN.2017090958","volume":"29","author":"AS De Vriese","year":"2018","unstructured":"De Vriese, A. S., Sethi, S., Nath, K. A., Glassock, R. J. & Fervenza, F. C. Differentiating primary, genetic, and secondary FSGS in adults: a clinicopathologic approach. J. Am. Soc. Nephrol. 29, 759\u2013774 (2018). A critical reappraisal of diagnostic criteria for the recognition of many forms of podocytopathies.","journal-title":"J. Am. Soc. Nephrol."},{"key":"196_CR51","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1681\/ASN.2017020174","volume":"28","author":"R Nishizono","year":"2017","unstructured":"Nishizono, R. et al. FSGS as an adaptive response to growth-induced podocyte stress. J. Am. Soc. Nephrol. 28, 2931\u20132945 (2017).","journal-title":"J. Am. Soc. Nephrol."},{"key":"196_CR52","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1681\/ASN.2008070709","volume":"20","author":"E Ronconi","year":"2009","unstructured":"Ronconi, E. et al. Regeneration of glomerular podocytes by human renal progenitors. J. Am. Soc. Nephrol. 20, 322\u2013332 (2009).","journal-title":"J. Am. Soc. Nephrol."},{"key":"196_CR53","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.kint.2018.08.013","volume":"94","author":"S Romoli","year":"2018","unstructured":"Romoli, S. et al. CXCL12 blockade preferentially regenerates lost podocytes in cortical nephrons by targeting an intrinsic podocyte-progenitor feedback mechanism. Kidney Int. 94, 1111\u20131126 (2018).","journal-title":"Kidney Int."},{"key":"196_CR54","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.kint.2019.03.014","volume":"96","author":"NV Kaverina","year":"2019","unstructured":"Kaverina, N. V. et al. Dual lineage tracing shows that glomerular parietal epithelial cells can transdifferentiate toward the adult podocyte fate. Kidney Int. 96, 597\u2013611 (2019).","journal-title":"Kidney Int."},{"key":"196_CR55","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1038\/ki.2015.152","volume":"88","author":"DG Eng","year":"2015","unstructured":"Eng, D. G. et al. Glomerular parietal epithelial cells contribute to adult podocyte regeneration in experimental focal segmental glomerulosclerosis. Kidney Int. 88, 999\u20131012 (2015).","journal-title":"Kidney Int."},{"key":"196_CR56","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/j.kint.2017.04.026","volume":"92","author":"Y Dai","year":"2017","unstructured":"Dai, Y. et al. Retinoic acid improves nephrotoxic serum-induced glomerulonephritis through activation of podocyte retinoic acid receptor alpha. Kidney Int. 92, 1444\u20131457 (2017).","journal-title":"Kidney Int."},{"key":"196_CR57","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1159\/000342808","volume":"121","author":"J Zhang","year":"2012","unstructured":"Zhang, J. et al. Retinoids augment the expression of podocyte proteins by glomerular parietal epithelial cells in experimental glomerular disease. Nephron Exp. Nephrol. 121, e23\u2013e37 (2012).","journal-title":"Nephron Exp. Nephrol."},{"key":"196_CR58","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1681\/ASN.2012090950","volume":"24","author":"A Peired","year":"2013","unstructured":"Peired, A. et al. Proteinuria impairs podocyte regeneration by sequestering retinoic acid. J. Am. Soc. Nephrol. 24, 1756\u20131768 (2013).","journal-title":"J. Am. Soc. Nephrol."},{"key":"196_CR59","doi-asserted-by":"crossref","first-page":"F463","DOI":"10.1152\/ajprenal.00233.2019","volume":"317","author":"V Kumar","year":"2019","unstructured":"Kumar, V. & Singhal, P. C. APOL1 and kidney cell function. Am. J. Physiol. Renal Physiol. 317, F463\u2013F477 (2019).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"196_CR60","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.3390\/cells8121561","volume":"8","author":"ME Melica","year":"2019","unstructured":"Melica, M. E. et al. Substrate stiffness modulates renal progenitor cell properties via a ROCK-mediated mechanotransduction mechanism. Cells 8, 1561 (2019).","journal-title":"Cells"},{"key":"196_CR61","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/nm1731","volume":"14","author":"T Niranjan","year":"2008","unstructured":"Niranjan, T. et al. The Notch pathway in podocytes plays a role in the development of glomerular disease. Nat. Med. 14, 290\u2013298 (2008).","journal-title":"Nat. Med."},{"key":"196_CR62","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.stemcr.2015.07.003","volume":"5","author":"L Lasagni","year":"2015","unstructured":"Lasagni, L. et al. Podocyte regeneration driven by renal progenitors determines glomerular disease remission and can be pharmacologically enhanced. Stem Cell Rep. 5, 248\u2013263 (2015). A proof-of-concept study that shows podocyte regeneration occurs after damage and can be pharmacologically enhanced.","journal-title":"Stem Cell Rep."},{"key":"196_CR63","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1681\/ASN.2009020132","volume":"20","author":"B Smeets","year":"2009","unstructured":"Smeets, B. et al. Renal progenitor cells contribute to hyperplastic lesions of podocytopathies and crescentic glomerulonephritis. J. Am. Soc. Nephrol. 20, 2593\u20132603 (2009).","journal-title":"J. Am. Soc. Nephrol."},{"key":"196_CR64","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2215\/CJN.04120417","volume":"13","author":"JK Warejko","year":"2018","unstructured":"Warejko, J. K. et al. Whole exome sequencing of patients with steroid-resistant nephrotic syndrome. Clin. J. Am. Soc. Nephrol. 13, 53\u201362 (2018).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"196_CR65","unstructured":"Landini, S. et al. Reverse phenotyping after whole-exome sequencing in steroid-resistant nephrotic syndrome. Clin. J. Am. Soc. Nephrol. (2019). A study reporting the high prevalence of genetic cases caused by unrecognized syndromic disorders in up to 60% of patients with SRNS."},{"key":"196_CR66","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1681\/ASN.2017010027","volume":"28","author":"S Assady","year":"2017","unstructured":"Assady, S., Wanner, N., Skorecki, K. L. & Huber, T. B. New insights into podocyte biology in glomerular health and disease. J. Am. Soc. Nephrol. 28, 1707\u20131715 (2017).","journal-title":"J. Am. Soc. Nephrol."},{"key":"196_CR67","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1681\/ASN.2013111155","volume":"26","author":"S Giglio","year":"2015","unstructured":"Giglio, S. et al. Heterogeneous genetic alterations in sporadic nephrotic syndrome associate with resistance to immunosuppression. J. Am. Soc. Nephrol. 26, 230\u2013236 (2015).","journal-title":"J. Am. Soc. Nephrol."},{"key":"196_CR68","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1681\/ASN.2014050489","volume":"26","author":"CE Sadowski","year":"2015","unstructured":"Sadowski, C. E. et al. A single-gene cause in 29.5% of cases of steroid-resistant nephrotic syndrome. J. Am. Soc. Nephrol. 26, 1279\u20131289 (2015). A large-scale study reporting the presence of primary genetic podocytopathies in 29.5% of cases of SRNS.","journal-title":"J. Am. Soc. Nephrol."},{"key":"196_CR69","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1681\/ASN.2017121265","volume":"29","author":"AT van der Ven","year":"2018","unstructured":"van der Ven, A. T. et al. Whole-exome sequencing identifies causative mutations in families with congenital anomalies of the kidney and urinary tract. J. Am. Soc. Nephrol. 29, 2348\u20132361 (2018).","journal-title":"J. Am. Soc. Nephrol."},{"key":"196_CR70","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-04193-w","volume":"9","author":"S Ashraf","year":"2018","unstructured":"Ashraf, S. et al. Mutations in six nephrosis genes delineate a pathogenic pathway amenable to treatment. Nat. Commun. 9, 1960 (2018).","journal-title":"Nat. Commun."},{"key":"196_CR71","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s00467-017-3819-9","volume":"33","author":"G Dorval","year":"2018","unstructured":"Dorval, G. et al. Clinical and genetic heterogeneity in familial steroid-sensitive nephrotic syndrome. Pediatr. Nephrol. 33, 473\u2013483 (2018).","journal-title":"Pediatr. Nephrol."},{"key":"196_CR72","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbadis.2013.10.007","volume":"1842","author":"M Doimo","year":"2014","unstructured":"Doimo, M. et al. Effect of vanillic acid on COQ6 mutants identified in patients with coenzyme Q10 deficiency. Biochim. Biophys. Acta 1842, 1\u20136 (2014).","journal-title":"Biochim. Biophys. Acta"},{"key":"196_CR73","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1007\/s00467-017-3634-3","volume":"32","author":"M Atmaca","year":"2017","unstructured":"Atmaca, M. et al. Follow-up results of patients with ADCK4 mutations and the efficacy of CoQ10 treatment. Pediatr. Nephrol. 32, 1369\u20131375 (2017).","journal-title":"Pediatr. Nephrol."},{"key":"196_CR74","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1056\/NEJMoa1109122","volume":"365","author":"O Boyer","year":"2011","unstructured":"Boyer, O. et al. INF2 mutations in Charcot-Marie-Tooth disease with glomerulopathy. N. Engl. J. Med. 365, 2377\u20132388 (2011).","journal-title":"N. Engl. J. Med."},{"key":"196_CR75","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1007\/s10157-018-1629-4","volume":"23","author":"K Nozu","year":"2019","unstructured":"Nozu, K. et al. A review of clinical characteristics and genetic backgrounds in Alport syndrome. Clin. Exp. Nephrol. 23, 158\u2013168 (2019).","journal-title":"Clin. Exp. Nephrol."},{"key":"196_CR76","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.krcp.2015.03.003","volume":"34","author":"TH Yoo","year":"2015","unstructured":"Yoo, T. H. & Fornoni, A. Nonimmunologic targets of immunosuppressive agents in podocytes. Kidney Res. Clin. Pract. 34, 69\u201375 (2015).","journal-title":"Kidney Res. Clin. Pract."},{"key":"196_CR77","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/S0140-6736(74)91880-7","volume":"2","author":"RJ Shalhoub","year":"1974","unstructured":"Shalhoub, R. J. Pathogenesis of lipoid nephrosis: a disorder of T-cell function. Lancet 2, 556\u2013560 (1974).","journal-title":"Lancet"},{"key":"196_CR78","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1159\/000085357","volume":"25","author":"MJ Kemper","year":"2005","unstructured":"Kemper, M. J., Zepf, K., Klaassen, I., Link, A. & Muller-Wiefel, D. E. Changes of lymphocyte populations in pediatric steroid-sensitive nephrotic syndrome are more pronounced in remission than in relapse. Am. J. Nephrol. 25, 132\u2013137 (2005).","journal-title":"Am. J. Nephrol."},{"key":"196_CR79","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1007\/s00467-009-1194-x","volume":"24","author":"XS Shao","year":"2009","unstructured":"Shao, X. S. et al. The prevalence of Th17 cells and FOXP3 regulate T cells (Treg) in children with primary nephrotic syndrome. Pediatr. Nephrol. 24, 1683\u20131690 (2009).","journal-title":"Pediatr. Nephrol."},{"key":"196_CR80","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s00467-006-0026-5","volume":"21","author":"CE Araya","year":"2006","unstructured":"Araya, C. E. et al. A case of unfulfilled expectations. Cytokines in idiopathic minimal lesion nephrotic syndrome. Pediatr. Nephrol. 21, 603\u2013610 (2006).","journal-title":"Pediatr. Nephrol."},{"key":"196_CR81","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1681\/ASN.2006070710","volume":"18","author":"KW Lai","year":"2007","unstructured":"Lai, K. W. et al. Overexpression of interleukin-13 induces minimal-change-like nephropathy in rats. J. Am. Soc. Nephrol. 18, 1476\u20131485 (2007).","journal-title":"J. Am. Soc. Nephrol."},{"key":"196_CR82","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.clim.2011.02.018","volume":"139","author":"LL Liu","year":"2011","unstructured":"Liu, L. L. et al. Th17\/Treg imbalance in adult patients with minimal change nephrotic syndrome. Clin. Immunol. 139, 314\u2013320 (2011).","journal-title":"Clin. Immunol."},{"key":"196_CR83","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/ped.13255","volume":"59","author":"S Tsuji","year":"2017","unstructured":"Tsuji, S. et al. Regulatory T cells and CTLA-4 in idiopathic nephrotic syndrome. Pediatr. Int. 59, 643\u2013646 (2017).","journal-title":"Pediatr. Int."},{"key":"196_CR84","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1007\/s00467-009-1119-8","volume":"24","author":"Y Hashimura","year":"2009","unstructured":"Hashimura, Y. et al. Minimal change nephrotic syndrome associated with immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome. Pediatr. Nephrol. 24, 1181\u20131186 (2009).","journal-title":"Pediatr. Nephrol."},{"key":"196_CR85","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/S0140-6736(14)60541-9","volume":"384","author":"K Iijima","year":"2014","unstructured":"Iijima, K. et al. Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 384, 1273\u20131281 (2014).","journal-title":"Lancet"},{"key":"196_CR86","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1681\/ASN.2013030251","volume":"25","author":"P Ruggenenti","year":"2014","unstructured":"Ruggenenti, P. et al. Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome. J. Am. Soc. Nephrol. 25, 850\u2013863 (2014). A study establishing the efficacy of rituximab for treatment of FRNS.","journal-title":"J. Am. Soc. Nephrol."},{"key":"196_CR87","doi-asserted-by":"crossref","first-page":"85ra46","DOI":"10.1126\/scitranslmed.3002231","volume":"3","author":"A Fornoni","year":"2011","unstructured":"Fornoni, A. et al. Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci. Transl Med. 3, 85ra46 (2011).","journal-title":"Sci. Transl Med."},{"key":"196_CR88","doi-asserted-by":"crossref","first-page":"bcr2015210208","DOI":"10.1136\/bcr-2015-210208","volume":"2015","author":"A Bonanni","year":"2015","unstructured":"Bonanni, A., Rossi, R., Murtas, C. & Ghiggeri, G. M. Low-dose ofatumumab for rituximab-resistant nephrotic syndrome. BMJ Case Rep. 2015, bcr2015210208 (2015).","journal-title":"BMJ Case Rep."},{"key":"196_CR89","volume":"2","author":"AH Kim","year":"2017","unstructured":"Kim, A. H. et al. B cell-derived IL-4 acts on podocytes to induce proteinuria and foot process effacement. JCI Insight 2, e81836 (2017).","journal-title":"JCI Insight"},{"key":"196_CR90","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1681\/ASN.V991709","volume":"9","author":"J Dantal","year":"1998","unstructured":"Dantal, J. et al. Antihuman immunoglobulin affinity immunoadsorption strongly decreases proteinuria in patients with relapsing nephrotic syndrome. J. Am. Soc. Nephrol. 9, 1709\u20131715 (1998).","journal-title":"J. Am. Soc. Nephrol."},{"key":"196_CR91","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/s41390-018-0088-7","volume":"84","author":"D Bhatia","year":"2018","unstructured":"Bhatia, D. et al. Rituximab modulates T- and B-lymphocyte subsets and urinary CD80 excretion in patients with steroid-dependent nephrotic syndrome. Pediatr. Res. 84, 520\u2013526 (2018).","journal-title":"Pediatr. Res."},{"key":"196_CR92","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.kint.2019.04.006","volume":"96","author":"M Colucci","year":"2019","unstructured":"Colucci, M. et al. Atypical IgM on T cells predict relapse and steroid dependence in idiopathic nephrotic syndrome. Kidney Int. 96, 971\u2013982 (2019).","journal-title":"Kidney Int."},{"key":"196_CR93","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1056\/NEJM199604043341402","volume":"334","author":"VJ Savin","year":"1996","unstructured":"Savin, V. J. et al. Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis. N. Engl. J. Med. 334, 878\u2013883 (1996).","journal-title":"N. Engl. J. Med."},{"key":"196_CR94","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1097\/00007890-199410000-00018","volume":"58","author":"AA Ali","year":"1994","unstructured":"Ali, A. A. et al. Minimal-change glomerular nephritis. Normal kidneys in an abnormal environment? Transplantation 58, 849\u2013852 (1994).","journal-title":"Transplantation"},{"key":"196_CR95","doi-asserted-by":"crossref","first-page":"256ra136","DOI":"10.1126\/scitranslmed.3008538","volume":"6","author":"M Delville","year":"2014","unstructured":"Delville, M. et al. A circulating antibody panel for pretransplant prediction of FSGS recurrence after kidney transplantation. Sci. Transl Med. 6, 256ra136 (2014).","journal-title":"Sci. Transl Med."},{"key":"196_CR96","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1038\/nm.2411","volume":"17","author":"C Wei","year":"2011","unstructured":"Wei, C. et al. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat. Med. 17, 952\u2013960 (2011).","journal-title":"Nat. Med."},{"key":"196_CR97","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nm.4242","volume":"23","author":"E Hahm","year":"2017","unstructured":"Hahm, E. et al. Bone marrow-derived immature myeloid cells are a main source of circulating suPAR contributing to proteinuric kidney disease. Nat. Med. 23, 100\u2013106 (2017).","journal-title":"Nat. Med."},{"key":"196_CR98","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1093\/ndt\/gfu355","volume":"29","author":"RJ Maas","year":"2014","unstructured":"Maas, R. J., Deegens, J. K. & Wetzels, J. F. Permeability factors in idiopathic nephrotic syndrome: historical perspectives and lessons for the future. Nephrol. Dial. Transpl. 29, 2207\u20132216 (2014).","journal-title":"Nephrol. Dial. Transpl."},{"key":"196_CR99","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/nm.2261","volume":"17","author":"LC Clement","year":"2011","unstructured":"Clement, L. C. et al. Podocyte-secreted angiopoietin-like-4 mediates proteinuria in glucocorticoid-sensitive nephrotic syndrome. Nat. Med. 17, 117\u2013122 (2011).","journal-title":"Nat. Med."},{"key":"196_CR100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0176198","volume":"12","author":"G Cara-Fuentes","year":"2017","unstructured":"Cara-Fuentes, G. et al. Angiopoietin-like-4 and minimal change disease. PLoS ONE 12, e0176198 (2017).","journal-title":"PLoS ONE"},{"key":"196_CR101","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ckj\/sft002","volume":"6","author":"P Chandra","year":"2013","unstructured":"Chandra, P. & Kopp, J. B. Viruses and collapsing glomerulopathy: a brief critical review. Clin. Kidney J. 6, 1\u20135 (2013).","journal-title":"Clin. Kidney J."},{"key":"196_CR102","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1056\/NEJMra1508467","volume":"377","author":"SD Cohen","year":"2017","unstructured":"Cohen, S. D., Kopp, J. B. & Kimmel, P. L. Kidney diseases associated with human immunodeficiency virus infection. N. Engl. J. Med. 377, 2363\u20132374 (2017).","journal-title":"N. Engl. J. Med."},{"key":"196_CR103","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.ajpath.2013.04.017","volume":"183","author":"A Migliorini","year":"2013","unstructured":"Migliorini, A. et al. The antiviral cytokines IFN-\u03b1 and IFN-\u03b2 modulate parietal epithelial cells and promote podocyte loss: implications for IFN toxicity, viral glomerulonephritis, and glomerular regeneration. Am. J. Pathol. 183, 431\u2013440 (2013).","journal-title":"Am. J. Pathol."},{"key":"196_CR104","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0195443","volume":"13","author":"UE Ekrikpo","year":"2018","unstructured":"Ekrikpo, U. E. et al. Chronic kidney disease in the global adult HIV-infected population: a systematic review and meta-analysis. PLoS ONE 13, e0195443 (2018).","journal-title":"PLoS ONE"},{"key":"196_CR105","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3389\/fimmu.2019.00053","volume":"10","author":"P An","year":"2019","unstructured":"An, P. et al. Impact of APOL1 genetic variants on HIV-1 infection and disease progression. Front. Immunol. 10, 53 (2019).","journal-title":"Front. Immunol."},{"key":"196_CR106","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3389\/fmed.2019.00020","volume":"6","author":"A Angeletti","year":"2019","unstructured":"Angeletti, A., Cantarelli, C. & Cravedi, P. HCV-associated nephropathies in the era of direct acting antiviral agents. Front. Med. 6, 20 (2019).","journal-title":"Front. Med."},{"key":"196_CR107","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1053\/j.ackd.2015.06.003","volume":"22","author":"A Gupta","year":"2015","unstructured":"Gupta, A. & Quigg, R. J. Glomerular diseases associated with hepatitis B and C. Adv. Chronic Kidney Dis. 22, 343\u2013351 (2015).","journal-title":"Adv. Chronic Kidney Dis."},{"key":"196_CR108","first-page":"20","volume":"25","author":"C Sanchez","year":"2012","unstructured":"Sanchez, C., Fenves, A. & Schwartz, J. Focal segmental glomerulosclerosis and parvovirus B19. Proc. (Bayl. Univ. Med. Cent.) 25, 20\u201322 (2012).","journal-title":"Proc. (Bayl. Univ. Med. Cent.)"},{"key":"196_CR109","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/S0272-6386(00)70055-2","volume":"35","author":"S Tanawattanacharoen","year":"2000","unstructured":"Tanawattanacharoen, S., Falk, R. J., Jennette, J. C. & Kopp, J. B. Parvovirus B19 DNA in kidney tissue of patients with focal segmental glomerulosclerosis. Am. J. Kidney Dis. 35, 1166\u20131174 (2000).","journal-title":"Am. J. Kidney Dis."},{"key":"196_CR110","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.ekir.2020.04.030","volume":"5","author":"SH Nasr","year":"2020","unstructured":"Nasr, S. H. & Kopp, J. B. COVID-19-associated collapsing glomerulopathy: an emerging entity. Kidney Int. Rep. 5, 759\u2013761 (2020).","journal-title":"Kidney Int. Rep."},{"key":"196_CR111","first-page":"294532","volume":"2012","author":"E Kwiatkowska","year":"2012","unstructured":"Kwiatkowska, E., Golembiewska, E., Ciechanowski, K. & Kedzierska, K. Minimal-change disease secondary to Borrelia burgdorferi infection. Case Rep. Nephrol. 2012, 294532 (2012).","journal-title":"Case Rep. Nephrol."},{"key":"196_CR112","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1146\/annurev-physiol-021115-105412","volume":"78","author":"CS Bartlett","year":"2016","unstructured":"Bartlett, C. S., Jeansson, M. & Quaggin, S. E. Vascular growth factors and glomerular disease. Annu. Rev. Physiol. 78, 437\u2013461 (2016).","journal-title":"Annu. Rev. Physiol."},{"key":"196_CR113","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/ki.2014.17","volume":"86","author":"IM Craici","year":"2014","unstructured":"Craici, I. M., Wagner, S. J., Weissgerber, T. L., Grande, J. P. & Garovic, V. D. Advances in the pathophysiology of pre-eclampsia and related podocyte injury. Kidney Int. 86, 275\u2013285 (2014).","journal-title":"Kidney Int."},{"key":"196_CR114","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1093\/ndt\/gfu368","volume":"30","author":"M Ollero","year":"2015","unstructured":"Ollero, M. & Sahali, D. Inhibition of the VEGF signalling pathway and glomerular disorders. Nephrol. Dial. Transpl. 30, 1449\u20131455 (2015).","journal-title":"Nephrol. Dial. Transpl."},{"key":"196_CR115","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/MD.0000000000000207","volume":"93","author":"H Izzedine","year":"2014","unstructured":"Izzedine, H. et al. Kidney diseases associated with anti-vascular endothelial growth factor (VEGF): an 8-year observational study at a single center. Medicine 93, 333\u2013339 (2014).","journal-title":"Medicine"},{"key":"196_CR116","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1681\/ASN.V1261164","volume":"12","author":"GS Markowitz","year":"2001","unstructured":"Markowitz, G. S. et al. Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J. Am. Soc. Nephrol. 12, 1164\u20131172 (2001).","journal-title":"J. Am. Soc. Nephrol."},{"key":"196_CR117","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.126124","volume":"4","author":"M Aghajan","year":"2019","unstructured":"Aghajan, M. et al. Antisense oligonucleotide treatment ameliorates IFN-\u03b3-induced proteinuria in APOL1-transgenic mice. JCI Insight 4, e126124 (2019).","journal-title":"JCI Insight"},{"key":"196_CR118","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-08235-1","volume":"10","author":"JA Hurcombe","year":"2019","unstructured":"Hurcombe, J. A. et al. Podocyte GSK3 is an evolutionarily conserved critical regulator of kidney function. Nat. Commun. 10, 403 (2019).","journal-title":"Nat. Commun."},{"key":"196_CR119","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1007\/s00467-001-0809-7","volume":"17","author":"A Sakarcan","year":"2002","unstructured":"Sakarcan, A., Thomas, D. B., O\u2019Reilly, K. P. & Richards, R. W. Lithium-induced nephrotic syndrome in a young pediatric patient. Pediatr. Nephrol. 17, 290\u2013292 (2002).","journal-title":"Pediatr. Nephrol."},{"key":"196_CR120","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1016\/j.ajpath.2014.06.027","volume":"184","author":"W Xu","year":"2014","unstructured":"Xu, W., Ge, Y., Liu, Z. & Gong, R. Glycogen synthase kinase 3\u03b2 dictates podocyte motility and focal adhesion turnover by modulating paxillin activity: implications for the protective effect of low-dose lithium in podocytopathy. Am. J. Pathol. 184, 2742\u20132756 (2014).","journal-title":"Am. J. Pathol."},{"key":"196_CR121","doi-asserted-by":"crossref","first-page":"326","DOI":"10.2215\/CJN.03751106","volume":"2","author":"E Letavernier","year":"2007","unstructured":"Letavernier, E. et al. High sirolimus levels may induce focal segmental glomerulosclerosis de novo. Clin. J. Am. Soc. Nephrol. 2, 326\u2013333 (2007).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"196_CR122","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.99271","volume":"4","author":"VG Puelles","year":"2019","unstructured":"Puelles, V. G. et al. mTOR-mediated podocyte hypertrophy regulates glomerular integrity in mice and humans. JCI Insight 4, e99271 (2019).","journal-title":"JCI Insight"},{"key":"196_CR123","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0080340","volume":"8","author":"S Muller-Krebs","year":"2013","unstructured":"Muller-Krebs, S. et al. Cellular effects of everolimus and sirolimus on podocytes. PLoS ONE 8, e80340 (2013).","journal-title":"PLoS ONE"},{"key":"196_CR124","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1002\/path.4193","volume":"230","author":"SR Mulay","year":"2013","unstructured":"Mulay, S. R. et al. Podocyte loss involves MDM2-driven mitotic catastrophe. J. Pathol. 230, 322\u2013335 (2013).","journal-title":"J. Pathol."},{"key":"196_CR125","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/ki.1986.36","volume":"29","author":"GA Kaysen","year":"1986","unstructured":"Kaysen, G. A., Gambertoglio, J., Jimenez, I., Jones, H. & Hutchison, F. N. Effect of dietary protein intake on albumin homeostasis in nephrotic patients. Kidney Int. 29, 572\u2013577 (1986).","journal-title":"Kidney Int."},{"key":"196_CR126","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1172\/JCI113000","volume":"79","author":"HJ Moshage","year":"1987","unstructured":"Moshage, H. J., Janssen, J. A., Franssen, J. H., Hafkenscheid, J. C. & Yap, S. H. Study of the molecular mechanism of decreased liver synthesis of albumin in inflammation. J. Clin. Invest. 79, 1635\u20131641 (1987).","journal-title":"J. Clin. Invest."},{"key":"196_CR127","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/MNH.0000000000000578","volume":"29","author":"GR Hinrichs","year":"2020","unstructured":"Hinrichs, G. R., Jensen, B. L. & Svenningsen, P. Mechanisms of sodium retention in nephrotic syndrome. Curr. Opin. Nephrol. Hypertens. 29, 207\u2013212 (2020).","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"196_CR128","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1007\/s00467-013-2435-6","volume":"28","author":"D Bockenhauer","year":"2013","unstructured":"Bockenhauer, D. Over- or underfill: not all nephrotic states are created equal. Pediatr. Nephrol. 28, 1153\u20131156 (2013).","journal-title":"Pediatr. Nephrol."},{"key":"196_CR129","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1681\/ASN.V102323","volume":"10","author":"JG Vande Walle","year":"1999","unstructured":"Vande Walle, J. G., Donckerwolcke, R. A. & Koomans, H. A. Pathophysiology of edema formation in children with nephrotic syndrome not due to minimal change disease. J. Am. Soc. Nephrol. 10, 323\u2013331 (1999).","journal-title":"J. Am. Soc. Nephrol."},{"key":"196_CR130","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S0140-6736(95)91210-X","volume":"346","author":"JG Vande Walle","year":"1995","unstructured":"Vande Walle, J. G. et al. Volume regulation in children with early relapse of minimal-change nephrosis with or without hypovolaemic symptoms. Lancet 346, 148\u2013152 (1995).","journal-title":"Lancet"},{"key":"196_CR131","doi-asserted-by":"crossref","first-page":"242","DOI":"10.7326\/0003-4819-60-2-242","volume":"60","author":"H Yamauchi","year":"1964","unstructured":"Yamauchi, H. & Hopper, J., Jr, Hypovolemic shock and hypotension as a complication in the nephrotic syndrome. report of ten cases. Ann. Intern. Med. 60, 242\u2013254 (1964).","journal-title":"Ann. Intern. Med."},{"key":"196_CR132","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1002\/ajh.2830440411","volume":"44","author":"TY Chen","year":"1993","unstructured":"Chen, T. Y., Huang, C. C. & Tsao, C. J. Hemostatic molecular markers in nephrotic syndrome. Am. J. Hematol. 44, 276\u2013279 (1993).","journal-title":"Am. J. Hematol."},{"key":"196_CR133","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1056\/NEJMcibr1209459","volume":"368","author":"J Loscalzo","year":"2013","unstructured":"Loscalzo, J. Venous thrombosis in the nephrotic syndrome. N. Engl. J. Med. 368, 956\u2013958 (2013).","journal-title":"N. Engl. J. Med."},{"key":"196_CR134","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.thromres.2005.03.030","volume":"118","author":"R Singhal","year":"2006","unstructured":"Singhal, R. & Brimble, K. S. Thromboembolic complications in the nephrotic syndrome: pathophysiology and clinical management. Thromb. Res. 118, 397\u2013407 (2006).","journal-title":"Thromb. Res."},{"key":"196_CR135","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nrneph.2017.155","volume":"14","author":"S Agrawal","year":"2018","unstructured":"Agrawal, S., Zaritsky, J. J., Fornoni, A. & Smoyer, W. E. Dyslipidaemia in nephrotic syndrome: mechanisms and treatment. Nat. Rev. Nephrol. 14, 57\u201370 (2018). An extensive critical reassessment of the pathogenetic mechanisms of dyslipidaemia in nephrotic syndrome.","journal-title":"Nat. Rev. Nephrol."},{"key":"196_CR136","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1056\/NEJM199008303230905","volume":"323","author":"J Joven","year":"1990","unstructured":"Joven, J. et al. Abnormalities of lipoprotein metabolism in patients with the nephrotic syndrome. N. Engl. J. Med. 323, 579\u2013584 (1990).","journal-title":"N. Engl. J. Med."},{"key":"196_CR137","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/nm.3396","volume":"20","author":"LC Clement","year":"2014","unstructured":"Clement, L. C. et al. Circulating angiopoietin-like 4 links proteinuria with hypertriglyceridemia in nephrotic syndrome. Nat. Med. 20, 37\u201346 (2014).","journal-title":"Nat. Med."},{"key":"196_CR138","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1007\/s00467-016-3555-6","volume":"32","author":"F Iorember","year":"2017","unstructured":"Iorember, F. & Aviles, D. Anemia in nephrotic syndrome: approach to evaluation and treatment. Pediatr. Nephrol. 32, 1323\u20131330 (2017).","journal-title":"Pediatr. Nephrol."},{"key":"196_CR139","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s00467-015-3236-x","volume":"31","author":"DT Selewski","year":"2016","unstructured":"Selewski, D. T. et al. Vitamin D in incident nephrotic syndrome: a Midwest Pediatric Nephrology Consortium study. Pediatr. Nephrol. 31, 465\u2013472 (2016).","journal-title":"Pediatr. Nephrol."},{"key":"196_CR140","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/j.1440-1754.2004.00285.x","volume":"40","author":"RK Alwadhi","year":"2004","unstructured":"Alwadhi, R. K., Mathew, J. L. & Rath, B. Clinical profile of children with nephrotic syndrome not on glucorticoid therapy, but presenting with infection. J. Paediatr. Child. Health 40, 28\u201332 (2004).","journal-title":"J. Paediatr. Child. Health"},{"key":"196_CR141","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1542\/peds.42.4.667","volume":"42","author":"CM Wilfert","year":"1968","unstructured":"Wilfert, C. M. & Katz, S. L. Etiology of bacterial sepsis in nephrotic children 1963-1967. Pediatrics 42, 840\u2013843 (1968).","journal-title":"Pediatrics"},{"key":"196_CR142","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S0022-3476(82)80633-1","volume":"100","author":"M Ballow","year":"1982","unstructured":"Ballow, M., Kennedy, T. L. III, Gaudio, K. M., Siegel, N. J. & McLean, R. H. Serum hemolytic factor D values in children with steroid-responsive idiopathic nephrotic syndrome. J. Pediatr. 100, 192\u2013196 (1982).","journal-title":"J. Pediatr."},{"key":"196_CR143","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/infdis\/140.1.1","volume":"140","author":"DC Anderson","year":"1979","unstructured":"Anderson, D. C., York, T. L., Rose, G. & Smith, C. W. Assessment of serum factor B, serum opsonins, granulocyte chemotaxis, and infection in nephrotic syndrome of children. J. Infect. Dis. 140, 1\u201311 (1979).","journal-title":"J. Infect. Dis."},{"key":"196_CR144","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S0022-3476(82)80287-4","volume":"101","author":"VM Vehaskari","year":"1982","unstructured":"Vehaskari, V. M. & Rapola, J. Isolated proteinuria: analysis of a school-age population. J. Pediatr. 101, 661\u2013668 (1982).","journal-title":"J. Pediatr."},{"key":"196_CR145","doi-asserted-by":"crossref","first-page":"200","DOI":"10.3389\/fped.2018.00200","volume":"6","author":"A Trautmann","year":"2018","unstructured":"Trautmann, A., Lipska-Zietkiewicz, B. S. & Schaefer, F. Exploring the clinical and genetic spectrum of steroid resistant nephrotic syndrome: the PodoNet Registry. Front. Pediatr. 6, 200 (2018).","journal-title":"Front. Pediatr."},{"key":"196_CR146","doi-asserted-by":"crossref","first-page":"445","DOI":"10.2215\/CJN.03531006","volume":"2","author":"M Waldman","year":"2007","unstructured":"Waldman, M. et al. Adult minimal-change disease: clinical characteristics, treatment, and outcomes. Clin. J. Am. Soc. Nephrol. 2, 445\u2013453 (2007).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"196_CR147","doi-asserted-by":"crossref","first-page":"911","DOI":"10.2215\/CJN.01920219","volume":"14","author":"SM Korbet","year":"2019","unstructured":"Korbet, S. M. & Whittier, W. L. Management of adult minimal change disease. Clin. J. Am. Soc. Nephrol. 14, 911\u2013913 (2019).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"196_CR148","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1542\/peds.105.6.1242","volume":"105","author":"RJ Hogg","year":"2000","unstructured":"Hogg, R. J. et al. Evaluation and management of proteinuria and nephrotic syndrome in children: recommendations from a pediatric nephrology panel established at the National Kidney Foundation conference on proteinuria, albuminuria, risk, assessment, detection, and elimination (PARADE). Pediatrics 105, 1242\u20131249 (2000).","journal-title":"Pediatrics"},{"key":"196_CR149","first-page":"248","volume":"95","author":"AK Leung","year":"2017","unstructured":"Leung, A. K., Wong, A. H. & Barg, S. S. Proteinuria in children: evaluation and differential diagnosis. Am. Fam. Physician 95, 248\u2013254 (2017).","journal-title":"Am. Fam. Physician"},{"key":"196_CR150","doi-asserted-by":"crossref","first-page":"3186","DOI":"10.1093\/ndt\/gfr750","volume":"27","author":"T Hama","year":"2012","unstructured":"Hama, T. et al. Renal biopsy criterion in children with asymptomatic constant isolated proteinuria. Nephrol. Dial. Transpl. 27, 3186\u20133190 (2012).","journal-title":"Nephrol. Dial. Transpl."},{"key":"196_CR151","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/j.1651-2227.2006.tb02352.x","volume":"95","author":"YM Lee","year":"2006","unstructured":"Lee, Y. M. et al. Analysis of renal biopsies performed in children with abnormal findings in urinary mass screening. Acta Paediatr. 95, 849\u2013853 (2006).","journal-title":"Acta Paediatr."},{"key":"196_CR152","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/ki.1978.23","volume":"13","author":"Nephrotic syndrome in children: prediction of histopathology from clinical and laboratory characteristics at time of diagnosis","year":"1978","unstructured":"Nephrotic syndrome in children: prediction of histopathology from clinical and laboratory characteristics at time of diagnosis. A report of the International Study of Kidney Disease in Children. Kidney Int. 13, 159\u2013165 (1978).","journal-title":"Kidney Int."},{"key":"196_CR153","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.2215\/CJN.05260610","volume":"6","author":"S Santin","year":"2011","unstructured":"Santin, S. et al. Clinical utility of genetic testing in children and adults with steroid-resistant nephrotic syndrome. Clin. J. Am. Soc. Nephrol. 6, 1139\u20131148 (2011).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"196_CR154","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.kint.2018.07.024","volume":"94","author":"O Gribouval","year":"2018","unstructured":"Gribouval, O. et al. Identification of genetic causes for sporadic steroid-resistant nephrotic syndrome in adults. Kidney Int. 94, 1013\u20131022 (2018).","journal-title":"Kidney Int."},{"key":"196_CR155","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.kint.2018.10.031","volume":"95","author":"DM Connaughton","year":"2019","unstructured":"Connaughton, D. M. et al. Monogenic causes of chronic kidney disease in adults. Kidney Int. 95, 914\u2013928 (2019).","journal-title":"Kidney Int."},{"key":"196_CR156","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.13371019","author":"AE Mason","year":"2020","unstructured":"Mason, A. E. et al. Response to first course of intensified immunosuppression in genetically-stratified steroid resistant nephrotic syndrome. Clin. J. Am. Soc. Nephrol. https:\/\/doi.org\/10.2215\/CJN.13371019 (2020).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"196_CR157","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1038\/ki.2012.280","volume":"82","author":"J Radhakrishnan","year":"2012","unstructured":"Radhakrishnan, J. & Cattran, D. C. The KDIGO practice guideline on glomerulonephritis: reading between the (guide)lines\u2013application to the individual patient. Kidney Int. 82, 840\u2013856 (2012).","journal-title":"Kidney Int."},{"key":"196_CR158","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s00467-019-04225-7","volume":"35","author":"J Zhao","year":"2020","unstructured":"Zhao, J. & Liu, Z. Treatment of nephrotic syndrome: going beyond immunosuppressive therapy. Pediatr. Nephrol. 35, 569\u2013579 (2020).","journal-title":"Pediatr. Nephrol."},{"key":"196_CR159","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1093\/oxfordjournals.ndt.a027136","volume":"11","author":"SK Mak","year":"1996","unstructured":"Mak, S. K., Short, C. D. & Mallick, N. P. Long-term outcome of adult-onset minimal-change nephropathy. Nephrol. Dial. Transpl. 11, 2192\u20132201 (1996).","journal-title":"Nephrol. Dial. Transpl."},{"key":"196_CR160","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1681\/ASN.2012040389","volume":"23","author":"SM Korbet","year":"2012","unstructured":"Korbet, S. M. Treatment of primary FSGS in adults. J. Am. Soc. Nephrol. 23, 1769\u20131776 (2012).","journal-title":"J. Am. Soc. Nephrol."},{"key":"196_CR161","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1681\/ASN.2004070593","volume":"16","author":"S Troyanov","year":"2005","unstructured":"Troyanov, S. et al. Focal and segmental glomerulosclerosis: definition and relevance of a partial remission. J. Am. Soc. Nephrol. 16, 1061\u20131068 (2005).","journal-title":"J. Am. Soc. Nephrol."},{"key":"196_CR162","first-page":"115","volume":"33","author":"M Wehrmann","year":"1990","unstructured":"Wehrmann, M. et al. Long-term prognosis of focal sclerosing glomerulonephritis. An analysis of 250 cases with particular regard to tubulointerstitial changes. Clin. Nephrol. 33, 115\u2013122 (1990).","journal-title":"Clin. Nephrol."},{"key":"196_CR163","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1038\/sj.ki.4491164","volume":"56","author":"VC Chitalia","year":"1999","unstructured":"Chitalia, V. C., Wells, J. E., Robson, R. A., Searle, M. & Lynn, K. L. Predicting renal survival in primary focal glomerulosclerosis from the time of presentation. Kidney Int. 56, 2236\u20132242 (1999).","journal-title":"Kidney Int."},{"key":"196_CR164","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.1681\/ASN.2016101121","volume":"28","author":"A Trautmann","year":"2017","unstructured":"Trautmann, A. et al. Long-term outcome of steroid-resistant nephrotic syndrome in children. J. Am. Soc. Nephrol. 28, 3055\u20133065 (2017).","journal-title":"J. Am. Soc. Nephrol."},{"key":"196_CR165","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1172\/JCI129937","volume":"130","author":"M Bedin","year":"2020","unstructured":"Bedin, M. et al. Human C-terminal CUBN variants associate with chronic proteinuria and normal renal function. J. Clin. Invest. 130, 335\u2013344 (2020). This paper identified a genetic form of proteinuria and podocytopathy that does not progress to ESKD.","journal-title":"J. Clin. Invest."},{"key":"196_CR166","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1172\/JCI45693","volume":"121","author":"SF Heeringa","year":"2011","unstructured":"Heeringa, S. F. et al. COQ6 mutations in human patients produce nephrotic syndrome with sensorineural deafness. J. Clin. Invest. 121, 2013\u20132024 (2011).","journal-title":"J. Clin. Invest."},{"key":"196_CR167","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/S0272-6386(12)80483-5","volume":"17","author":"M Praga","year":"1991","unstructured":"Praga, M. et al. Nephrotic proteinuria without hypoalbuminemia: clinical characteristics and response to angiotensin-converting enzyme inhibition. Am. J. Kidney Dis. 17, 330\u2013338 (1991).","journal-title":"Am. J. Kidney Dis."},{"key":"196_CR168","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1681\/ASN.V85824","volume":"8","author":"BM Tune","year":"1997","unstructured":"Tune, B. M. & Mendoza, S. A. Treatment of the idiopathic nephrotic syndrome: regimens and outcomes in children and adults. J. Am. Soc. Nephrol. 8, 824\u2013832 (1997).","journal-title":"J. Am. Soc. Nephrol."},{"key":"196_CR169","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/j.1651-2227.1984.tb17767.x","volume":"73","author":"K Murnaghan","year":"1984","unstructured":"Murnaghan, K., Vasmant, D. & Bensman, A. Pulse methylprednisolone therapy in severe idiopathic childhood nephrotic syndrome. Acta Paediatr. Scand. 73, 733\u2013739 (1984).","journal-title":"Acta Paediatr. Scand."},{"key":"196_CR170","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1007\/s00467-015-3106-6","volume":"30","author":"EM Hodson","year":"2015","unstructured":"Hodson, E. M., Hahn, D. & Craig, J. C. Corticosteroids for the initial episode of steroid-sensitive nephrotic syndrome. Pediatr. Nephrol. 30, 1043\u20131046 (2015).","journal-title":"Pediatr. Nephrol."},{"key":"196_CR171","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1136\/archdischild-2015-308924","volume":"101","author":"N Larkins","year":"2016","unstructured":"Larkins, N., Kim, S., Craig, J. & Hodson, E. Steroid-sensitive nephrotic syndrome: an evidence-based update of immunosuppressive treatment in children. Arch. Dis. Child. 101, 404\u2013408 (2016).","journal-title":"Arch. Dis. Child."},{"key":"196_CR172","first-page":"CD001537","volume":"2008","author":"SC Palmer","year":"2008","unstructured":"Palmer, S. C., Nand, K. & Strippoli, G. F. Interventions for minimal change disease in adults with nephrotic syndrome. Cochrane Database Syst. Rev. 2008, CD001537 (2008).","journal-title":"Cochrane Database Syst. Rev."},{"key":"196_CR173","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1136\/bmj.3.5720.421","volume":"3","author":"DA Black","year":"1970","unstructured":"Black, D. A., Rose, G. & Brewer, D. B. Controlled trial of prednisone in adult patients with the nephrotic syndrome. Br. Med. J. 3, 421\u2013426 (1970).","journal-title":"Br. Med. J."},{"key":"196_CR174","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2215\/CJN.06180519","volume":"15","author":"NR Medjeral-Thomas","year":"2020","unstructured":"Medjeral-Thomas, N. R. et al. Randomized, controlled trial of tacrolimus and prednisolone monotherapy for adults with de novo minimal change disease: a multicenter, randomized, controlled trial. Clin. J. Am. Soc. Nephrol. 15, 209\u2013218 (2020).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"196_CR175","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.kint.2018.07.021","volume":"94","author":"P Remy","year":"2018","unstructured":"Remy, P. et al. An open-label randomized controlled trial of low-dose corticosteroid plus enteric-coated mycophenolate sodium versus standard corticosteroid treatment for minimal change nephrotic syndrome in adults (MSN Study). Kidney Int. 94, 1217\u20131226 (2018).","journal-title":"Kidney Int."},{"key":"196_CR176","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1093\/ndt\/gfm538","volume":"23","author":"L Senthil Nayagam","year":"2008","unstructured":"Senthil Nayagam, L. et al. Mycophenolate mofetil or standard therapy for membranous nephropathy and focal segmental glomerulosclerosis: a pilot study. Nephrol. Dial. Transpl. 23, 1926\u20131930 (2008).","journal-title":"Nephrol. Dial. Transpl."},{"key":"196_CR177","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.kint.2018.11.008","volume":"95","author":"BH Rovin","year":"2019","unstructured":"Rovin, B. H. et al. Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 95, 281\u2013295 (2019).","journal-title":"Kidney Int."},{"key":"196_CR178","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/ki.2012.412","volume":"83","author":"RJ Glassock","year":"2013","unstructured":"Glassock, R. J. Therapy of relapsing minimal-change disease in adults: a new approach? Kidney Int. 83, 343\u2013345 (2013).","journal-title":"Kidney Int."},{"key":"196_CR179","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/0272-6386(95)90120-5","volume":"25","author":"JJ Rydel","year":"1995","unstructured":"Rydel, J. J., Korbet, S. M., Borok, R. Z. & Schwartz, M. M. Focal segmental glomerular sclerosis in adults: presentation, course, and response to treatment. Am. J. Kidney Dis. 25, 534\u2013542 (1995).","journal-title":"Am. J. Kidney Dis."},{"key":"196_CR180","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s00467-018-4149-2","volume":"34","author":"C Dossier","year":"2019","unstructured":"Dossier, C. et al. Five-year outcome of children with idiopathic nephrotic syndrome: the NEPHROVIR population-based cohort study. Pediatr. Nephrol. 34, 671\u2013678 (2019).","journal-title":"Pediatr. Nephrol."},{"key":"196_CR181","first-page":"CD001533","volume":"4","author":"EM Hodson","year":"2007","unstructured":"Hodson, E. M., Willis, N. S. & Craig, J. C. Corticosteroid therapy for nephrotic syndrome in children. Cochrane Database Syst. Rev. 4, CD001533 (2007).","journal-title":"Cochrane Database Syst. Rev."},{"key":"196_CR182","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1304572","volume":"369","author":"CC Yu","year":"2013","unstructured":"Yu, C. C. et al. Abatacept in B7-1-positive proteinuric kidney disease. N. Engl. J. Med. 369, 2416\u20132423 (2013).","journal-title":"N. Engl. J. Med."},{"key":"196_CR183","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00467-018-4119-8","volume":"34","author":"T Korsgaard","year":"2019","unstructured":"Korsgaard, T., Andersen, R. F., Joshi, S., Hagstrom, S. & Rittig, S. Childhood onset steroid-sensitive nephrotic syndrome continues into adulthood. Pediatr. Nephrol. 34, 641\u2013648 (2019).","journal-title":"Pediatr. Nephrol."},{"key":"196_CR184","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jpeds.2005.03.050","volume":"147","author":"EM Ruth","year":"2005","unstructured":"Ruth, E. M., Kemper, M. J., Leumann, E. P., Laube, G. F. & Neuhaus, T. J. Children with steroid-sensitive nephrotic syndrome come of age: long-term outcome. J. Pediatr. 147, 202\u2013207 (2005).","journal-title":"J. Pediatr."},{"key":"196_CR185","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.2215\/CJN.05691108","volume":"4","author":"HA Kyrieleis","year":"2009","unstructured":"Kyrieleis, H. A. et al. Long-term outcome of biopsy-proven, frequently relapsing minimal-change nephrotic syndrome in children. Clin. J. Am. Soc. Nephrol. 4, 1593\u20131600 (2009).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"196_CR186","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s00467-012-2310-x","volume":"28","author":"RM Lombel","year":"2013","unstructured":"Lombel, R. M., Gipson, D. S. & Hodson, E. M., Kidney Disease: Improving Global Outcomes. Treatment of steroid-sensitive nephrotic syndrome: new guidelines from KDIGO. Pediatr. Nephrol. 28, 415\u2013426 (2013).","journal-title":"Pediatr. Nephrol."},{"key":"196_CR187","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1053\/j.ajkd.2013.12.002","volume":"63","author":"S Samuel","year":"2014","unstructured":"Samuel, S. et al. Canadian society of nephrology commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis: management of nephrotic syndrome in children. Am. J. Kidney Dis. 63, 354\u2013362 (2014).","journal-title":"Am. J. Kidney Dis."},{"key":"196_CR188","first-page":"1326","volume":"8","author":"C Ponticelli","year":"1993","unstructured":"Ponticelli, C. et al. Cyclosporin versus cyclophosphamide for patients with steroid-dependent and frequently relapsing idiopathic nephrotic syndrome: a multicentre randomized controlled trial. Nephrol. Dial. Transpl. 8, 1326\u20131332 (1993).","journal-title":"Nephrol. Dial. Transpl."},{"key":"196_CR189","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.kint.2018.08.039","volume":"95","author":"A Sinha","year":"2019","unstructured":"Sinha, A. et al. Efficacy and safety of mycophenolate mofetil versus levamisole in frequently relapsing nephrotic syndrome: an open-label randomized controlled trial. Kidney Int. 95, 210\u2013218 (2019).","journal-title":"Kidney Int."},{"key":"196_CR190","first-page":"CD002290","volume":"10","author":"N Pravitsitthikul","year":"2013","unstructured":"Pravitsitthikul, N., Willis, N. S., Hodson, E. M. & Craig, J. C. Non-corticosteroid immunosuppressive medications for steroid-sensitive nephrotic syndrome in children. Cochrane Database Syst. Rev. 10, CD002290 (2013).","journal-title":"Cochrane Database Syst. Rev."},{"key":"196_CR191","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s00431-012-1913-3","volume":"172","author":"S Fujinaga","year":"2013","unstructured":"Fujinaga, S. et al. Cyclosporine versus mycophenolate mofetil for maintenance of remission of steroid-dependent nephrotic syndrome after a single infusion of rituximab. Eur. J. Pediatr. 172, 513\u2013518 (2013).","journal-title":"Eur. J. Pediatr."},{"key":"196_CR192","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1007\/s00467-008-0899-6","volume":"23","author":"EM Dorresteijn","year":"2008","unstructured":"Dorresteijn, E. M. et al. Mycophenolate mofetil versus cyclosporine for remission maintenance in nephrotic syndrome. Pediatr. Nephrol. 23, 2013\u20132020 (2008).","journal-title":"Pediatr. Nephrol."},{"key":"196_CR193","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.2215\/CJN.02840313","volume":"8","author":"J Hogan","year":"2013","unstructured":"Hogan, J. et al. Treatment of idiopathic FSGS with adrenocorticotropic hormone gel. Clin. J. Am. Soc. Nephrol. 8, 2072\u20132081 (2013).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"196_CR194","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1093\/ckj\/sfw045","volume":"9","author":"W Kittanamongkolchai","year":"2016","unstructured":"Kittanamongkolchai, W., Cheungpasitporn, W. & Zand, L. Efficacy and safety of adrenocorticotropic hormone treatment in glomerular diseases: a systematic review and meta-analysis. Clin. Kidney J. 9, 387\u2013396 (2016).","journal-title":"Clin. Kidney J."},{"key":"196_CR195","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1007\/s00467-013-2483-y","volume":"28","author":"C Straatmann","year":"2013","unstructured":"Straatmann, C. et al. Treatment outcome of late steroid-resistant nephrotic syndrome: a study by the Midwest Pediatric Nephrology Consortium. Pediatr. Nephrol. 28, 1235\u20131241 (2013).","journal-title":"Pediatr. Nephrol."},{"key":"196_CR196","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1038\/ki.1993.194","volume":"43","author":"C Ponticelli","year":"1993","unstructured":"Ponticelli, C. et al. A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome. Kidney Int. 43, 1377\u20131384 (1993).","journal-title":"Kidney Int."},{"key":"196_CR197","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1093\/ndt\/gfl805","volume":"22","author":"A Segarra","year":"2007","unstructured":"Segarra, A. et al. Efficacy and safety of \u2018rescue therapy\u2019 with mycophenolate mofetil in resistant primary glomerulonephritis \u2013 a multicenter study. Nephrol. Dial. Transpl. 22, 1351\u20131360 (2007).","journal-title":"Nephrol. Dial. Transpl."},{"key":"196_CR198","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/ki.2011.195","volume":"80","author":"DS Gipson","year":"2011","unstructured":"Gipson, D. S. et al. Clinical trial of focal segmental glomerulosclerosis in children and young adults. Kidney Int. 80, 868\u2013878 (2011).","journal-title":"Kidney Int."},{"key":"196_CR199","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1093\/ndt\/gfr572","volume":"27","author":"J Gellermann","year":"2012","unstructured":"Gellermann, J., Ehrich, J. H. & Querfeld, U. Sequential maintenance therapy with cyclosporin A and mycophenolate mofetil for sustained remission of childhood steroid-resistant nephrotic syndrome. Nephrol. Dial. Transpl. 27, 1970\u20131978 (2012).","journal-title":"Nephrol. Dial. Transpl."},{"key":"196_CR200","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1681\/ASN.2015091002","volume":"27","author":"M Delville","year":"2016","unstructured":"Delville, M. et al. B7-1 blockade does not improve post-transplant nephrotic syndrome caused by recurrent FSGS. J. Am. Soc. Nephrol. 27, 2520\u20132527 (2016).","journal-title":"J. Am. Soc. Nephrol."},{"key":"196_CR201","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1056\/NEJMc1400502","volume":"370","author":"A Benigni","year":"2014","unstructured":"Benigni, A., Gagliardini, E. & Remuzzi, G. Abatacept in B7-1-positive proteinuric kidney disease. N. Engl. J. Med. 370, 1261\u20131263 (2014).","journal-title":"N. Engl. J. Med."},{"key":"196_CR202","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1159\/000360908","volume":"39","author":"A Kronbichler","year":"2014","unstructured":"Kronbichler, A. et al. Rituximab treatment for relapsing minimal change disease and focal segmental glomerulosclerosis: a systematic review. Am. J. Nephrol. 39, 322\u2013330 (2014).","journal-title":"Am. J. Nephrol."},{"key":"196_CR203","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12882-015-0094-5","volume":"16","author":"H Trachtman","year":"2015","unstructured":"Trachtman, H. et al. Efficacy of galactose and adalimumab in patients with resistant focal segmental glomerulosclerosis: report of the font clinical trial group. BMC Nephrol. 16, 111 (2015).","journal-title":"BMC Nephrol."},{"key":"196_CR204","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1681\/ASN.2018010091","volume":"29","author":"H Trachtman","year":"2018","unstructured":"Trachtman, H. et al. DUET: a phase 2 study evaluating the efficacy and safety of sparsentan in patients with FSGS. J. Am. Soc. Nephrol. 29, 2745\u20132754 (2018).","journal-title":"J. Am. Soc. Nephrol."},{"issue":"Suppl. 4","key":"196_CR205","doi-asserted-by":"crossref","first-page":"iv124","DOI":"10.1093\/ndt\/gfu028","volume":"29","author":"O Gross","year":"2014","unstructured":"Gross, O., Perin, L. & Deltas, C. Alport syndrome from bench to bedside: the potential of current treatment beyond RAAS blockade and the horizon of future therapies. Nephrol. Dial. Transpl. 29 (Suppl. 4), iv124\u2013iv130 (2014).","journal-title":"Nephrol. Dial. Transpl."},{"key":"196_CR206","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/j.ekir.2018.06.003","volume":"3","author":"AK Solanki","year":"2018","unstructured":"Solanki, A. K. et al. A novel CLCN5 mutation associated with focal segmental glomerulosclerosis and podocyte injury. Kidney Int. Rep. 3, 1443\u20131453 (2018).","journal-title":"Kidney Int. Rep."},{"key":"196_CR207","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/cge.13007","volume":"92","author":"M du Moulin","year":"2017","unstructured":"du Moulin, M. et al. The mutation p.D313Y is associated with organ manifestation in Fabry disease. Clin. Genet. 92, 528\u2013533 (2017).","journal-title":"Clin. Genet."},{"key":"196_CR208","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1093\/ndt\/gfg473","volume":"19","author":"M Hu","year":"2004","unstructured":"Hu, M. et al. Prophylactic bilateral nephrectomies in two paediatric patients with missense mutations in the WT1 gene. Nephrol. Dial. Transpl. 19, 223\u2013226 (2004).","journal-title":"Nephrol. Dial. Transpl."},{"key":"196_CR209","doi-asserted-by":"crossref","first-page":"245","DOI":"10.5414\/CNP62245","volume":"62","author":"RJ Crew","year":"2004","unstructured":"Crew, R. J., Radhakrishnan, J. & Appel, G. Complications of the nephrotic syndrome and their treatment. Clin. Nephrol. 62, 245\u2013259 (2004).","journal-title":"Clin. Nephrol."},{"key":"196_CR210","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/clpt.1982.187","volume":"32","author":"E Keller","year":"1982","unstructured":"Keller, E., Hoppe-Seyler, G. & Schollmeyer, P. Disposition and diuretic effect of furosemide in the nephrotic syndrome. Clin. Pharmacol. Ther. 32, 442\u2013449 (1982).","journal-title":"Clin. Pharmacol. Ther."},{"key":"196_CR211","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1053\/j.ajkd.2016.08.027","volume":"69","author":"EJ Hoorn","year":"2017","unstructured":"Hoorn, E. J. & Ellison, D. H. Diuretic resistance. Am. J. Kidney Dis. 69, 136\u2013142 (2017).","journal-title":"Am. J. Kidney Dis."},{"key":"196_CR212","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1053\/j.ajkd.2016.10.022","volume":"69","author":"MA Fallahzadeh","year":"2017","unstructured":"Fallahzadeh, M. A. et al. Acetazolamide and hydrochlorothiazide followed by furosemide versus furosemide and hydrochlorothiazide followed by furosemide for the treatment of adults with nephrotic edema: a randomized trial. Am. J. Kidney Dis. 69, 420\u2013427 (2017).","journal-title":"Am. J. Kidney Dis."},{"key":"196_CR213","doi-asserted-by":"crossref","DOI":"10.1111\/apha.13249","volume":"225","author":"F Artunc","year":"2019","unstructured":"Artunc, F., Worn, M., Schork, A. & Bohnert, B. N. Proteasuria \u2013 the impact of active urinary proteases on sodium retention in nephrotic syndrome. Acta Physiol. 225, e13249 (2019).","journal-title":"Acta Physiol."},{"key":"196_CR214","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.kint.2017.07.023","volume":"93","author":"BN Bohnert","year":"2018","unstructured":"Bohnert, B. N. et al. Aprotinin prevents proteolytic epithelial sodium channel (ENaC) activation and volume retention in nephrotic syndrome. Kidney Int. 93, 159\u2013172 (2018).","journal-title":"Kidney Int."},{"key":"196_CR215","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0272-6386(12)80994-2","volume":"23","author":"DC Wheeler","year":"1994","unstructured":"Wheeler, D. C. & Bernard, D. B. Lipid abnormalities in the nephrotic syndrome: causes, consequences, and treatment. Am. J. Kidney Dis. 23, 331\u2013346 (1994).","journal-title":"Am. J. Kidney Dis."},{"key":"196_CR216","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/ki.1985.149","volume":"28","author":"F Llach","year":"1985","unstructured":"Llach, F. Hypercoagulability, renal vein thrombosis, and other thrombotic complications of nephrotic syndrome. Kidney Int. 28, 429\u2013439 (1985).","journal-title":"Kidney Int."},{"key":"196_CR217","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jpeds.2009.01.070","volume":"155","author":"BA Kerlin","year":"2009","unstructured":"Kerlin, B. A. et al. Epidemiology and risk factors for thromboembolic complications of childhood nephrotic syndrome: a Midwest Pediatric Nephrology Consortium (MWPNC) study. J. Pediatr. 155, 105\u2013110 (2009).","journal-title":"J. Pediatr."},{"key":"196_CR218","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s10157-013-0917-2","volume":"18","author":"D Suri","year":"2014","unstructured":"Suri, D. et al. Thromboembolic complications in childhood nephrotic syndrome: a clinical profile. Clin. Exp. Nephrol. 18, 803\u2013813 (2014).","journal-title":"Clin. Exp. Nephrol."},{"key":"196_CR219","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.clinimag.2005.01.026","volume":"29","author":"B Rai Mittal","year":"2005","unstructured":"Rai Mittal, B., Singh, S., Bhattacharya, A., Prasad, V. & Singh, B. Lung scintigraphy in the diagnosis and follow-up of pulmonary thromboembolism in children with nephrotic syndrome. Clin. Imaging 29, 313\u2013316 (2005).","journal-title":"Clin. Imaging"},{"key":"196_CR220","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s12882-019-1336-8","volume":"20","author":"S Kelddal","year":"2019","unstructured":"Kelddal, S., Nykjaer, K. M., Gregersen, J. W. & Birn, H. Prophylactic anticoagulation in nephrotic syndrome prevents thromboembolic complications. BMC Nephrol. 20, 139 (2019).","journal-title":"BMC Nephrol."},{"key":"196_CR221","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/S0140-6736(81)90822-9","volume":"2","author":"GC Close","year":"1981","unstructured":"Close, G. C. & Houston, I. B. Fatal haemorrhagic chickenpox in a child on long-term steroids. Lancet 2, 480 (1981).","journal-title":"Lancet"},{"key":"196_CR222","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jpeds.2017.12.061","volume":"196","author":"K Kamei","year":"2018","unstructured":"Kamei, K. et al. Prospective study of live attenuated vaccines for patients with nephrotic syndrome receiving immunosuppressive agents. J. Pediatr. 196, 217\u2013222.e1 (2018).","journal-title":"J. Pediatr."},{"key":"196_CR223","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1007\/s00467-017-3793-2","volume":"33","author":"A Bierzynska","year":"2018","unstructured":"Bierzynska, A. & Saleem, M. A. Deriving and understanding the risk of post-transplant recurrence of nephrotic syndrome in the light of current molecular and genetic advances. Pediatr. Nephrol. 33, 2027\u20132035 (2018).","journal-title":"Pediatr. Nephrol."},{"key":"196_CR224","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-58197-y","volume":"10","author":"C Jacobs-Cacha","year":"2020","unstructured":"Jacobs-Cacha, C. et al. A misprocessed form of apolipoprotein A-I is specifically associated with recurrent focal segmental glomerulosclerosis. Sci. Rep. 10, 1159 (2020).","journal-title":"Sci. Rep."},{"key":"196_CR225","doi-asserted-by":"crossref","first-page":"2818","DOI":"10.1111\/ajt.14998","volume":"18","author":"K Kienzl-Wagner","year":"2018","unstructured":"Kienzl-Wagner, K. et al. Successful management of recurrent focal segmental glomerulosclerosis. Am. J. Transpl. 18, 2818\u20132822 (2018).","journal-title":"Am. J. Transpl."},{"key":"196_CR226","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s12882-016-0322-7","volume":"17","author":"A Kashgary","year":"2016","unstructured":"Kashgary, A. et al. The role of plasma exchange in treating post-transplant focal segmental glomerulosclerosis: a systematic review and meta-analysis of 77 case-reports and case-series. BMC Nephrol. 17, 104 (2016).","journal-title":"BMC Nephrol."},{"key":"196_CR227","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1681\/ASN.2018060575","volume":"30","author":"N Mann","year":"2019","unstructured":"Mann, N. et al. Whole-exome sequencing enables a precision medicine approach for kidney transplant recipients. J. Am. Soc. Nephrol. 30, 201\u2013215 (2019).","journal-title":"J. Am. Soc. Nephrol."},{"key":"196_CR228","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.kint.2018.12.018","volume":"95","author":"PA Canetta","year":"2019","unstructured":"Canetta, P. A. et al. Health-related quality of life in glomerular disease. Kidney Int. 95, 1209\u20131224 (2019).","journal-title":"Kidney Int."},{"key":"196_CR229","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.2215\/CJN.01520209","volume":"4","author":"S Kengne-Wafo","year":"2009","unstructured":"Kengne-Wafo, S. et al. Risk factors for cyclosporin a nephrotoxicity in children with steroid-dependant nephrotic syndrome. Clin. J. Am. Soc. Nephrol. 4, 1409\u20131416 (2009).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"196_CR230","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s00467-014-2955-8","volume":"30","author":"K Ishikura","year":"2015","unstructured":"Ishikura, K. et al. Morbidity in children with frequently relapsing nephrosis: 10-year follow-up of a randomized controlled trial. Pediatr. Nephrol. 30, 459\u2013468 (2015).","journal-title":"Pediatr. Nephrol."},{"key":"196_CR231","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1136\/ard.2008.092163","volume":"68","author":"D Huscher","year":"2009","unstructured":"Huscher, D. et al. Dose-related patterns of glucocorticoid-induced side effects. Ann. Rheum. Dis. 68, 1119\u20131124 (2009).","journal-title":"Ann. Rheum. Dis."},{"key":"196_CR232","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0022-3476(88)80260-9","volume":"113","author":"JS Hyams","year":"1988","unstructured":"Hyams, J. S. & Carey, D. E. Corticosteroids and growth. J. Pediatr. 113, 249\u2013254 (1988).","journal-title":"J. Pediatr."},{"key":"196_CR233","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1046\/j.1442-9071.2001.00426.x","volume":"29","author":"JS Ng","year":"2001","unstructured":"Ng, J. S. et al. Ocular complications of paediatric patients with nephrotic syndrome. Clin. Exp. Ophthalmol. 29, 239\u2013243 (2001).","journal-title":"Clin. Exp. Ophthalmol."},{"key":"196_CR234","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1651-2227.1986.tb10193.x","volume":"75","author":"C Polito","year":"1986","unstructured":"Polito, C., Oporto, M. R., Totino, S. F., La Manna, A. & Di Toro, R. Normal growth of nephrotic children during long-term alternate-day prednisone therapy. Acta Paediatr. Scand. 75, 245\u2013250 (1986).","journal-title":"Acta Paediatr. Scand."},{"key":"196_CR235","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s00467-016-3538-7","volume":"32","author":"J Hogan","year":"2017","unstructured":"Hogan, J. et al. Effect of center practices on the choice of the first dialysis modality for children and young adults. Pediatr. Nephrol. 32, 659\u2013667 (2017).","journal-title":"Pediatr. Nephrol."},{"key":"196_CR236","doi-asserted-by":"publisher","DOI":"10.1007\/s40620-019-00660-9","author":"W Morello","year":"2019","unstructured":"Morello, W. et al. Post-transplant recurrence of steroid resistant nephrotic syndrome in children: the Italian experience. J. Nephrol. https:\/\/doi.org\/10.1007\/s40620-019-00660-9 (2019).","journal-title":"J. Nephrol."},{"key":"196_CR237","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/ki.2012.428","volume":"83","author":"CA Gadegbeku","year":"2013","unstructured":"Gadegbeku, C. A. et al. Design of the Nephrotic Syndrome Study Network (NEPTUNE) to evaluate primary glomerular nephropathy by a multidisciplinary approach. Kidney Int. 83, 749\u2013756 (2013).","journal-title":"Kidney Int."},{"key":"196_CR238","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1053\/j.ajkd.2018.07.020","volume":"73","author":"LH Mariani","year":"2019","unstructured":"Mariani, L. H. et al. CureGN study rationale, design, and methods: establishing a large prospective observational study of glomerular disease. Am. J. Kidney Dis. 73, 218\u2013229 (2019).","journal-title":"Am. J. Kidney Dis."},{"key":"196_CR239","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s00467-017-3621-8","volume":"32","author":"CS Wang","year":"2017","unstructured":"Wang, C. S. et al. Ofatumumab for the treatment of childhood nephrotic syndrome. Pediatr. Nephrol. 32, 835\u2013841 (2017).","journal-title":"Pediatr. Nephrol."},{"key":"196_CR240","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s40265-018-0872-z","volume":"78","author":"HA Blair","year":"2018","unstructured":"Blair, H. A. & Duggan, S. T. Belimumab: a review in systemic lupus erythematosus. Drugs 78, 355\u2013366 (2018).","journal-title":"Drugs"},{"key":"196_CR241","unstructured":"KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney International Supplements (Elsevier, 2020)."},{"key":"196_CR242","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1007\/s00467-020-04519-1","volume":"35","author":"A Trautmann","year":"2020","unstructured":"Trautmann, A. et al. IPNA clinical practice recommendations for the diagnosis and management of children with steroid-resistant nephrotic syndrome. Pediatr. Nephrol. 35, 1529\u20131561 (2020).","journal-title":"Pediatr. Nephrol."},{"key":"196_CR243","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1053\/ajkd.2003.50116","volume":"41","author":"F Fakhouri","year":"2003","unstructured":"Fakhouri, F. et al. Steroid-sensitive nephrotic syndrome: from childhood to adulthood. Am. J. Kidney Dis. 41, 550\u2013557 (2003).","journal-title":"Am. J. Kidney Dis."},{"key":"196_CR244","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1136\/adc.2006.108985","volume":"92","author":"AS Abeyagunawardena","year":"2007","unstructured":"Abeyagunawardena, A. S., Hindmarsh, P. & Trompeter, R. S. Adrenocortical suppression increases the risk of relapse in nephrotic syndrome. Arch. Dis. Child. 92, 585\u2013588 (2007).","journal-title":"Arch. Dis. Child."},{"key":"196_CR245","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/S0022-3476(05)82020-7","volume":"125","author":"P Niaudet","year":"1994","unstructured":"Niaudet, P. Treatment of childhood steroid-resistant idiopathic nephrosis with a combination of cyclosporine and prednisone. French Society of Pediatric Nephrology. J. Pediatr. 125, 981\u2013986 (1994).","journal-title":"J. Pediatr."},{"key":"196_CR246","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.2215\/CJN.00110112","volume":"7","author":"K Ishikura","year":"2012","unstructured":"Ishikura, K. et al. Two-year follow-up of a prospective clinical trial of cyclosporine for frequently relapsing nephrotic syndrome in children. Clin. J. Am. Soc. Nephrol. 7, 1576\u20131583 (2012).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"196_CR247","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1681\/ASN.2012121200","volume":"24","author":"J Gellermann","year":"2013","unstructured":"Gellermann, J. et al. Mycophenolate mofetil versus cyclosporin A in children with frequently relapsing nephrotic syndrome. J. Am. Soc. Nephrol. 24, 1689\u20131697 (2013).","journal-title":"J. Am. Soc. Nephrol."},{"key":"196_CR248","first-page":"CD003233","volume":"2008","author":"N Braun","year":"2008","unstructured":"Braun, N. et al. Immunosuppressive treatment for focal segmental glomerulosclerosis in adults. Cochrane Database Syst. Rev. 2008, CD003233 (2008).","journal-title":"Cochrane Database Syst. Rev."},{"key":"196_CR249","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1093\/ndt\/gfi274","volume":"21","author":"MD Sinha","year":"2006","unstructured":"Sinha, M. D., MacLeod, R., Rigby, E. & Clark, A. G. Treatment of severe steroid-dependent nephrotic syndrome (SDNS) in children with tacrolimus. Nephrol. Dial. Transpl. 21, 1848\u20131854 (2006).","journal-title":"Nephrol. Dial. Transpl."},{"key":"196_CR250","doi-asserted-by":"crossref","first-page":"432","DOI":"10.5414\/CN107610","volume":"79","author":"ME Bock","year":"2013","unstructured":"Bock, M. E., Cohn, R. A. & Ali, F. N. Treatment of childhood nephrotic syndrome with long-term, low-dose tacrolimus. Clin. Nephrol. 79, 432\u2013438 (2013).","journal-title":"Clin. Nephrol."},{"key":"196_CR251","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ejps.2015.06.017","volume":"77","author":"J Sobiak","year":"2015","unstructured":"Sobiak, J. et al. Monitoring of mycophenolate mofetil metabolites in children with nephrotic syndrome and the proposed novel target values of pharmacokinetic parameters. Eur. J. Pharm. Sci. 77, 189\u2013196 (2015).","journal-title":"Eur. J. Pharm. Sci."},{"key":"196_CR252","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ajmg.a.32117","volume":"146A","author":"A Perez-Aytes","year":"2008","unstructured":"Perez-Aytes, A. et al. In utero exposure to mycophenolate mofetil: a characteristic phenotype? Am. J. Med. Genet. A 146A, 1\u20137 (2008).","journal-title":"Am. J. Med. Genet. A"},{"key":"196_CR253","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1093\/ndt\/gfu258","volume":"30","author":"K Kamei","year":"2015","unstructured":"Kamei, K. et al. Rituximab-associated agranulocytosis in children with refractory idiopathic nephrotic syndrome: case series and review of literature. Nephrol. Dial. Transpl. 30, 91\u201396 (2015).","journal-title":"Nephrol. Dial. Transpl."},{"key":"196_CR254","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1093\/ndt\/gfq665","volume":"26","author":"A McGrogan","year":"2011","unstructured":"McGrogan, A., Franssen, C. F. & de Vries, C. S. The incidence of primary glomerulonephritis worldwide: a systematic review of the literature. Nephrol. Dial. Transpl. 26, 414\u2013430 (2011).","journal-title":"Nephrol. Dial. Transpl."},{"key":"196_CR255","doi-asserted-by":"publisher","unstructured":"Cunningham, A., Benediktsson, H., Muruve, D. A., Hildebrand, A. M. & Ravani, P. Trends in biopsy-based diagnosis of kidney disease: a population study. Can. J. Kidney Health Dis. https:\/\/doi.org\/10.1177\/2054358118799690 (2018).","DOI":"10.1177\/2054358118799690"},{"key":"196_CR256","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1159\/000500142","volume":"5","author":"KT Woo","year":"2019","unstructured":"Woo, K. T. et al. A global evolutionary trend of the frequency of primary glomerulonephritis over the past four decades. Kidney Dis. 5, 247\u2013258 (2019).","journal-title":"Kidney Dis."},{"key":"196_CR257","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1093\/ndt\/gfx189","volume":"33","author":"MM O\u2019Shaughnessy","year":"2018","unstructured":"O\u2019Shaughnessy, M. M. et al. Glomerular disease frequencies by race, sex and region: results from the International Kidney Biopsy Survey. Nephrol. Dial. Transpl. 33, 661\u2013669 (2018).","journal-title":"Nephrol. Dial. Transpl."},{"key":"196_CR258","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1093\/ndt\/gfp355","volume":"25","author":"MG Polito","year":"2010","unstructured":"Polito, M. G., de Moura, L. A. & Kirsztajn, G. M. An overview on frequency of renal biopsy diagnosis in Brazil: clinical and pathological patterns based on 9,617 native kidney biopsies. Nephrol. Dial. Transpl. 25, 490\u2013496 (2010).","journal-title":"Nephrol. Dial. Transpl."},{"key":"196_CR259","doi-asserted-by":"crossref","first-page":"ii209","DOI":"10.1093\/ndt\/gfw365","volume":"32","author":"A Perkowska-Ptasinska","year":"2017","unstructured":"Perkowska-Ptasinska, A. et al. Clinicopathologic correlations of renal pathology in the adult population of Poland. Nephrol. Dial. Transpl. 32, ii209\u2013ii218 (2017).","journal-title":"Nephrol. Dial. Transpl."},{"key":"196_CR260","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1093\/ckj\/sfz023","volume":"12","author":"CM Zink","year":"2019","unstructured":"Zink, C. M. et al. Trends of renal diseases in Germany: review of a regional renal biopsy database from 1990 to 2013. Clin. Kidney J. 12, 795\u2013800 (2019).","journal-title":"Clin. Kidney J."},{"key":"196_CR261","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1007\/s11255-014-0838-3","volume":"46","author":"S Ozturk","year":"2014","unstructured":"Ozturk, S. et al. Demographic and clinical characteristics of primary glomerular diseases in Turkey. Int. Urol. Nephrol. 46, 2347\u20132355 (2014).","journal-title":"Int. Urol. Nephrol."},{"key":"196_CR262","doi-asserted-by":"crossref","first-page":"3040","DOI":"10.1093\/ndt\/gfh521","volume":"19","author":"I Rychlik","year":"2004","unstructured":"Rychlik, I. et al. The Czech registry of renal biopsies. Occurrence of renal diseases in the years 1994-2000. Nephrol. Dial. Transpl. 19, 3040\u20133049 (2004).","journal-title":"Nephrol. Dial. Transpl."},{"key":"196_CR263","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1093\/ndt\/gfv355","volume":"31","author":"S Lovric","year":"2016","unstructured":"Lovric, S., Ashraf, S., Tan, W. & Hildebrandt, F. Genetic testing in steroid-resistant nephrotic syndrome: when and how? Nephrol. Dial. Transpl. 31, 1802\u20131813 (2016).","journal-title":"Nephrol. Dial. Transpl."},{"key":"196_CR264","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1053\/j.ajkd.2003.10.024","volume":"43","author":"VD D\u2019Agati","year":"2004","unstructured":"D\u2019Agati, V. D., Fogo, A. B., Bruijn, J. A. & Jennette, J. C. Pathologic classification of focal segmental glomerulosclerosis: a working proposal. Am. J. Kidney Dis. 43, 368\u2013382 (2004).","journal-title":"Am. J. Kidney Dis."},{"key":"196_CR265","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/nrneph.2014.216","volume":"11","author":"AB Fogo","year":"2015","unstructured":"Fogo, A. B. Causes and pathogenesis of focal segmental glomerulosclerosis. Nat. Rev. Nephrol. 11, 76\u201387 (2015).","journal-title":"Nat. Rev. Nephrol."},{"key":"196_CR266","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1056\/NEJMra1106556","volume":"365","author":"VD D\u2019Agati","year":"2011","unstructured":"D\u2019Agati, V. D., Kaskel, F. J. & Falk, R. J. Focal segmental glomerulosclerosis. N. Engl. J. Med. 365, 2398\u20132411 (2011).","journal-title":"N. Engl. J. Med."},{"key":"196_CR267","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/j.kint.2017.09.028","volume":"93","author":"MS Hommos","year":"2018","unstructured":"Hommos, M. S. et al. Global glomerulosclerosis with nephrotic syndrome; the clinical importance of age adjustment. Kidney Int. 93, 1175\u20131182 (2018).","journal-title":"Kidney Int."},{"key":"196_CR268","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1038\/ki.2008.413","volume":"74","author":"JK Deegens","year":"2008","unstructured":"Deegens, J. K. et al. Podocyte foot process effacement as a diagnostic tool in focal segmental glomerulosclerosis. Kidney Int. 74, 1568\u20131576 (2008).","journal-title":"Kidney Int."}],"container-title":["Nature Reviews Disease Primers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41572-020-0196-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41572-020-0196-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41572-020-0196-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T18:22:19Z","timestamp":1733941339000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41572-020-0196-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,13]]},"references-count":268,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["196"],"URL":"https:\/\/doi.org\/10.1038\/s41572-020-0196-7","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.738490678.793592031","asserted-by":"object"}]},"ISSN":["2056-676X"],"issn-type":[{"value":"2056-676X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,13]]},"assertion":[{"value":"25 June 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"F.H. is a co-founder and member of the scientific advisory board of Goldfinch-Bio. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"68"}}